ID=H0480
URL=http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/articles//sarah99/sarah99.html
SIZE=67752
DATE=11/07/2002
TIME=17:05:34
DATASET=Biology
HTML=  
<html>
  <head>
    <title></title>
      <style type="text/css">
	<!--
	  span.red {color: red}
	  span.green {color: green}
          span.small {size:"-1"}
	  input.lavender {background: lavender;
			  color: green}
	  ul.tip {list-style-type: none} 
	  .a11 {color: black; 
                font-size: 11pt; 
                font-weight: normal; 
                text-decoration: none; 
                font-family: Arial, Helvetica, sans-serif}
          a:link {color: blue; 
                  text-decoration : none; 
                  font-weight: normal}
	  a:visited {color : blue;
                     text-decoration : none;
                     font-weight : normal}
          a:hover {color: brown; 
                   text-decoration : none; 
                   font-weight: normal}
#pup {position:absolute; visibility:hidden; z-index:200; width:130; }
//-->
      </style>	
  </head>
  <body bgcolor="white">
    <table bgcolor="white" width="100%" border=0 cellspacing=0 cellpadding=3>
      <tr valign="top">
	<td width="10%" bgcolor="#eaeaea">
               <!--
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>

<HEAD>
  <TITLE>
    HIV sequence database navigation frame
  </TITLE>
</HEAD>


<BODY> 
	BACKGROUND="" 
	BGCOLOR="#eaeaea" 
	TEXT="#000000" 
	LINK="#0000ff" 
	VLINK="#800080" 
	ALINK="#ff0000"
-->

<A HREF="/content/hiv-db/mainpage.html">
	
<IMG SRC="/content/hiv-db/IMAGES/VirusTransparent.gif" BORDER=0></A>

<P>
<CENTER>
</CENTER>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerDatabases.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/mainpage.html" 
	onMouseOver="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/_SequenceDB.gif' "
	onMouseOut="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif' " >
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif" BORDER=0 NAME="Sequence"></A><BR>

<A HREF="http://resdb.lanl.gov/Resist_DB/default.htm" 
	onMouseOver="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/_ResistanceDB.gif' "
	onMouseOut="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif'">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif" BORDER=0 NAME="Resistance"></A><BR>

<A HREF="/content/immunology/index" 
	onMouseOver="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/_ImmunologyDB.gif' "
	onMouseOut="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif" BORDER=0 NAME="Immunology"></A><BR>

<A HREF="/content/vaccine/html/index.html" 
	onMouseOver="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/_VaccinetrialsDB.gif' "
	onMouseOut="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif" BORDER=0 NAME="VaccineTrials"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerPublications.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/HTML/FAQ.html" 
	onMouseOver="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/_FAQ.gif' "
	onMouseOut="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif' ">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif" BORDER=0 NAME="Faq"></A><BR>

<A HREF="/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html" 
	onMouseOver="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/_Alignments.gif' "
	onMouseOut="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif" BORDER=0 NAME="Alignments"></A><BR>

<A HREF="/content/hiv-db/HTML/Tutorials.html" 
	onMouseOver="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tutorials.gif' "
	onMouseOut="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif" BORDER=0 NAME="Tutorials"></A><BR>

<A HREF="/content/hiv-db/REVIEWS/reviews.html" 
	onMouseOver="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/_Reviews.gif' "
	onMouseOut="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif" BORDER=0 NAME="Reviews"></A><BR>

<A HREF="/content/hiv-db/HTML/compendium.html" 
	onMouseOver="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/_Compendia.gif' "
	onMouseOut="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif" BORDER=0 NAME="Compendia"></A><BR>

<A HREF="/content/hiv-db/HTML/links.html" 
	onMouseOver="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/_Links.gif' "
	onMouseOut="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/Links.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Links.gif" BORDER=0 NAME="Links"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerSequenceDB.gif" BORDER=0></A><BR>

<!--
<A HREF="/content/hiv-db/MAP/hivmap.html" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Search&Align.gif'"
	onMouseOut="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif" BORDER=0 NAME="Hivmap"></A><BR>

<!--
<A HREF="/cgi-bin/hivDB3/public/wdb/ssampublic" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/_SearchDB.gif' "
	onMouseOut="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif" BORDER=0 NAME="Searchdb"></A><BR>

<A HREF="/content/hiv-db/HTML/tools.html" 
	onMouseOver="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tools.gif'"
	onMouseOut="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif" BORDER=0 NAME="Tools"></A><BR>

<A HREF="/content/hiv-db/BASIC_BLAST/basic_blast.html" 
	onMouseOver="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/_HIV-BLAST.gif' "
	onMouseOut="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif" BORDER=0 NAME="Hivblast"></A><BR>

<A HREF="http://linker.lanl.gov/RIP/RIPsubmit.html" 
	onMouseOver="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/_Recombination.gif' "
	onMouseOut="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif" BORDER=0 NAME="Rip"></A><BR>

<A HREF="/content/hiv-db/SNAP/WEBSNAP/SNAP.html" 
	onMouseOver="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Syn-Nonsyn.gif' "
	onMouseOut="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif" BORDER=0 NAME="Snap"></A><BR>

<A HREF="/content/hiv-db/HYPERMUT/hypermut.html" 
	onMouseOver="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/_Hypermut.gif' "
	onMouseOut="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif" BORDER=0 NAME="Hypermut"></A><BR>

<A HREF="/content/hiv-db/PCOORD/PCOORD.html" 
	onMouseOver="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/_PCOORD.gif' "
	onMouseOut="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif" BORDER=0 NAME="Pcoord"></A><BR>
    
<A HREF="/content/hiv-db/SUDI/sudi.html" 
	onMouseOver="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/_SUDI.gif' "
	onMouseOut="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif" BORDER=0 NAME="SUDI"></A><BR>

<A HREF="/content/hiv-db/CONTAM/TreeMaker/TreeMaker.html" 
	onMouseOver="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/_TreeMaker.gif' "
	onMouseOut="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif" BORDER=0 NAME="Treemaker"></A><BR>

<A HREF="/content/hiv-db/geography/map_right.html" 
	onMouseOver="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/_Geography.gif' "
	onMouseOut="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif" BORDER=0 NAME="Geography"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<!--
<br>
<small>
<small>
&nbsp;<a href="/content/hiv-db/combined_search/search">Combined Search</a>
</small>
</small>
</CENTER>
-->
<BR>
<BR>

<center>
<small>
<small>
<A HREF="http://www.lanl.gov/misc/disclaimer.html" >Disclaimer/Privacy</A>
</small>
</small>
<FONT FACE="Arial, Helvetica, sans-serif" SIZE="-2">
</FONT>
</center>

<!--
</BODY>
</HTML>
-->


        </td>
	<td>
	  <table border="0" cellspacing="0" cellpadding="3">
	    <tr><td>
            </td></tr>
	    <tr><td><html>
<head>
<title>Methods of Detection of HIV-specific CTL and Their Role in Protection Against HIV Infection</title>
<BODY BGCOLOR = "#FFFFFF"> 
<center><img src="../../../../IMAGES/newtoplogo2.gif"><P><BR>
<font size="+2">Methods of Detection of HIV-specific CTL and Their Role in Protection Against HIV Infection</font>
<P><hr noshade>
<b>Rupert Kaul and Sarah L. Rowland-Jones</b><br>
<br><i>John Radcliffe Hospital, Oxford OX3 9DS, U.K.</i>
<hr noshade><p>
</center>
<P>

<b><font size="+1">Introduction</font></b><p>
The observation that recovery from many virus infections is followed by the
development of lifelong immunity is a fundamental principal of vaccinology. In
contrast the perception that everyone who becomes infected with HIV remains
persistently infected and will ultimately develop disabling
immunodeficiency has been a serious discouragement to HIV vaccine development. In recent years a
number of studies have suggested that a handful of people with documented HIV
exposure who fail to seroconvert or develop detectable viraemia have a
range of HIV-specific responses. These observations clearly raise the
possibility that, under certain circumstances, HIV exposure can lead to potentially protective immune
responses. In this article we will first review the methods now available for the detection and quantitation of HIV-specific cytotoxic T-lymphocytes (CTL) and then discuss the detection and potential role of
HIV-specific CTL in highly-exposed persistently seronegative (HEPS) individuals.
<P>
<b><font size="+1">Measurement of HIV specific CTL</font></b><p>
One of the critical issues in interpreting the results of CTL studies in HEPS
subjects is the method used to measure HIV specific CTL, for which a number
of assay systems are employed.  In general, the choice of assay technique will
depend on the research question posed, the technical skill and experience of the
operator, the type of sample under study, and the degree to which results need to approximate the
in vivo milieu.  These techniques may measure CTL qualitatively or quantitatively; in
addition, it is possible to assess CTL responses directed against entire
HIV gene products, against predetermined CTL peptide epitopes, or against individual MHC
class I/peptide complexes.
<P>
<b>1. Bulk CTL culture</b><br>
The earliest description of HIV-specific CTL in HIV-infected people relied on
the lysis by freshly isolated peripheral blood mononuclear cells (PBMC) of
autologous B-cell lines (BCL) infected by recombinant vaccinia
viruses expressing HIV-1 gene products [Walker (1987), Plata (1987)]. It is
estimated that the detection of 'fresh" CTL lysis requires a frequency of circulating effector CTL of the
order of 1 in 100 [Gotch (1990)]. However, the use of fresh PBMC as effectors would be
expected to fail to detect CTL that are present at low frequency, as well as resting or memory CTL.
Somewhat surprisingly, two studies of uninfected infants born to infected mothers
described the detection of HIV-specific CTL activity using unstimulated PBMCs in between 26
and 75 of children [Cheynier(1992), DeMaria (1994)].
<p>
	More usually, CTL activity is detected by expanding HIV-specific CTL 
in vitro, using co-culture of bulk PBMC with inactivated, autologous antigen
presenting cells (APC) infected either by autologous virus [Nixon (1988)] or by recombinant vaccinia viruses
expressing HIV-1 gene products [Lubaki (1994), vanBaalen (1993)].  In this way, low frequency
antigen-specific CTL present in the original sample are clonally expanded, and are detected by the lysis of Cr51-pulsed,
class I MHC-matched targets, frequently autologous BCL. These
methods have been the staple of HIV CTL studies in seropositive donors for over a decade.
However, in HEPS donors who have no detectable viraemia, it is clearly not feasible to use
autologous virus to restimulate CTL cultures. Some authors have employed
stimulator cells infected with a laboratory strain of HIV [Fowke (1999)] or
used the recombinant vaccinia method [Bernard (1999)] to elicit HIV-specific CTL from HEPS
cohorts in vitro. In our experience, the most sensitive method for generating CTL cultures in HEPS
donors is the use of specific CTL epitope peptides selected on the basis of the HLA class I type of
that donor [RowlandJones (1995)]: the sensitivity of this method can be improved by the addition of IL-7
to the culture medium [Lalvani (1997), Rowland-Jones (1998)].
<p>
	Target cells may either be infected by recombinant vaccinia viruses expressing
HIV-1 gene products [Nixon (1988), Walker (1987)], or pulsed with specific HIV
CTL epitope peptides. Although there is some variation between laboratories, HIV-specific lysis
of 10--20 after a 4--6 hour assay, over a range of effector/target ratios (often
50:1, 25:1 and 12.5:1) and with a 50 reduction of target cell lysis after CD8+ depletion, is
generally used as the criterion for a positive CTL assay.
<p>
	As described, the bulk CTL assay has two major disadvantages.  The first is the
requirement for prolonged in vitro stimulation, which necessarily
results in the distortion of effector CTL frequency, and potentially their phenotype.
This technique is therefore poorly able to approximate conditions under which HIV-specific
lysis may occur in vivo.  A second disadvantage lies in the fact that CTL
bulk culture is a qualitative technique, useful only for HIV-specific CTL detection, rather than
quantitation.  This disadvantage can be overcome through the use of limiting
dilution analysis (LDA) [Koup (1991), Carmichael (1993)]. Here, fresh PBMC are
serially diluted, and these dilutions used to set up bulk CTL cultures. Mathematical techniques are
then applied to calculate the CTL effector frequency in the original sample, based on
the lowest dilution from which CTL can be detected after in vitro stimulation.
<p>
	CTL bulk culture techniques provide the clearest measurement of functional
CTL activity, since the assay end-point is the lysis by CTL of infected or
peptide-pulsed targets.  However, there are serious concerns that LDA may underestimate
the actual effector CTL frequency [Gotch (1990), Moss (1995)], and recent work in human
Epstein-Barr virus (EBV) infection has shown that LDA correlates only poorly with effector CD8+ T-cell frequencies estimated using
ELISpot assays or HLA-peptide tetrameric complexes [Tan (1999)]. The most
likely explanation for this is that LDA measures only the subset of virus-specific cells which
are able to grow and divide under limiting dilution conditions: this technique will
therefore miss those CTL which are terminally differentiated or prone to apoptosis in
tissue culture. This is likely to be a particular problem using cells from
HIV-infected people. In addition, bulk CTL techniques are time-consuming, require high input
numbers of effector cells, and involve the acquisition, handling and disposal of
radioactive materials. Nevertheless, this method has been successfully used to
demonstrate the presence of CTL precursors for a number of HIV gene products (particularly
gag and env) in 13 out of 36 HIV-exposed uninfected partners of HIV+ donors
[Goh (1999)].
<P>
<b>2)	Enzyme-linked immunospot (ELISpot) assay</b><br>
The ELISpot is based on the same principles as an ELISA assay. However, the
technique has been modified to permit the detection of cytokine release at
the single cell level in response to a given stimulus [Czerkinsky (1988), Quiding (1991)],
and has recently been applied to the enumeration of antigen-specific CD8+ T-cells
[DiFabio (1994), Miyahira (1995), Lalvani (1997a)].  In the ELISpot assay, nitrocellulose plates are coated with a first layer anti-cytokine antibody.
Effector cells are then incubated in the presence or absence of a specific stimulus; in
the HIV system, a suitable antigen can be a predefined HIV CTL epitope peptide
[Hanke (1998c), Rowland-Jones (1998), Herr (1998), Kaul (1999a)], or a class I MHC-matched target infected by recombinant
vaccinia expressing HIV-1 gene products [Larsson (1999)], or a laboratory strain of HIV
Zhang96. After incubation for 6--16 hours (overnight is convenient), cells are discarded, and the plate
incubated with a second biotinylated anti-cytokine antibody.  The use of an appropriate
detector system allows each cell producing cytokine to be detected as a separate spot.  These spots may
either be counted by eye under a dissecting microscope, or by a variety of
computer-assisted quantitation systems.  HIV specific responses are
calculated by the subtraction of background cytokine secretion (in response to media alone), and the
results are reported as spot-forming units (sfu) per  cells. We have used the
following criteria for a positive response: peptide-specific response at least twice that of
background, an absolute number of specific sfu of , and the
demonstration of a titratable response with varying numbers of input cells [Kaul (1999a)]. Other
authors have proposed a cut-off of specific sfu of  spots/well
[Lalvani (1997a)], and 10 spots/well [Larsson (1999)], as long as this number
is at least twice that observed in the negative control wells. Statistical
methods can also be applied to calculate the probablity that the response in
the experimental wells is significantly greater than the background secretion
of IFNg [Flanagan (1999)].
<P>
Although the ELISpot assay can be adapted to detect the release of any
cytokine, the quantitation of PBMC secreting IFNg in response to CTL epitope peptides
has been shown to correlate relatively well with CTL frequencies measured using lysis
assays (either bulk culture or LDA) and more closely with
HLA-peptide tetrameric complexes in a number of viral systems
[DiFabio (1994), Schmittel (1997), Lalvani (1997a), Tan (1999), Larsson (1999)].
In general, IFN- ELISpot frequencies are around 2--5 fold higher
than those measured using LDA bulk culture, and 2--5 fold lower than CTL frequencies measured using
tetramers [Tan (1999)].
<P>
Advantages of the ELISpot assay include its rapidity (an overnight assay, as
opposed to 12--14 days for bulk CTL); the ability to screen for responses
against multiple CTL epitopes and/or gene products in a single assay; and the need for
relatively low cell input numbers (generally 2--4  per epitope/gene product
tested). Of particular relevance in the study of HEPS individuals, where
HIV specific CTL frequencies seem likely to be considerably lower than seen in HIV infected
individuals [Goh (1999), Kaul (1999a)]; the sensitivity of the IFN ELISpot is greater than that of MHC class I/peptide
tetramers.  While ELISpot is able to detect antigen-specific responses to a
frequency of 1/50,000 input PBMC, tetramers currently have a threshold of
detection of 1/5,000 [Altman (1996)]. Finally, ELISpot detects antigen-specific CD8+ T-cells ex vivo, without
the need for prolonged these cells in vivo more accurately than bulk CTL cultures. However there are also disadvantages of this
assay system. Once the assay has been developed, the cells cannot be manipulated any
further, and usually only one cytokine can be measured at a time. Moreover, although it is assumed that IFN- secretion and cytolysis are
overlapping functions of antigen-specific CTL, this is not necessarily the case. Moreover, in a study
of the functional phenotype of tetramer-positive cells specific for HIV and
CMV antigens using intracytoplasmic staining for cytokines, although the great
majority of tetramer-staining cells produced IFN-, a significant
proportion (up to 25) did not produce TNF- (V. Appay, manuscript
submitted). Thus the TNF- Elispot assay would probably underestimate
the number of antigen-specific  cells detected using IFN- release.
<P>
The Elispot assay has been used in a number of studies of HEPS donors. We
detected responding CD8+ T-cell frequencies in response to particular HIV peptides of up to 1
in 3000 PBMC using an IFN- ELISpot in a cohort of highly-exposed sex
workers in Nairobi [Rowland-Jones (1998)]. In a survey of over 100 Nairobi prostitutes meeting
the definition of HIV resistance, over 50 showed significant ELISpot responses to a range of known
epitope peptides (R. Kaul, manuscript in preparation). An ELISpot assay for
tumour necrosis factor (TNF-) production was used to demonstrate responses to known HIV peptides presented by
HLA-A2 and A3 in 5 of 11 seronegative people with documented HIV exposure: in
this study, the frequencies of TNF-producing cells were in the order of
100--420 per PBMC [Herr (1998)].
<P>

<b>3) 	HLA-peptide tetrameric complexes</b><br>
	HLA-peptide complexes allow the direct visualisation of antigen-specific CD8+
T-cells, independent of their functional characteristics.   Four
biotinylated, refolded HLA-peptide complexes are attached to a streptavidin molecule, creating a
stable tetrameric structure which will specifically bind to T cells expressing an
appropriate T-cell receptor (TCR) [Altman (1996), Ogg (1998)]. Although this technique does not rely on a
functional endpoint, the antigen-specific CD8+ T-cell frequencies measured by flow cytometry have been
shown to correlate with functional cell populations by a number of methods,
including direct CTL lysis, CTL cloning, ELISpot and LDA [Ogg (1998), Dunbar (1998), Tan (1999)].  One of the
major advantages of the HLA-peptide tetramer technique is the ability to
examine the co-expression of other surface antigens [Ogg (1999a)], such as markers of
activation [Ogg (1998)], T-cell receptor V usage [Wilson (1998)] or indicators of apoptosis Tan99a.
More recently, the use of intracellular staining has permitted more detailed phenotypic analysis of
the virus-specific tetramer-positive population [Gillespie (1999)] (Victor
Appay, manuscript submitted). Another advantage is the ability to sort specifically a population of
antigen-specific cells, making growth and characterization of CTL clones relatively simple
[Dunbar (1998), Dunbar (1999)]. The technique is time-effective, able to yield results within a few hours of
blood being drawn, and works well with frozen cells.  The fact that PBMC can be stained
directly ex vivo means that, of the three techniques described, HLA-peptide tetramer
studies are most likely to accurately reflect the phenotype of antigen-specific CD8+ T-cells in vivo.
<P>
The major disadvantage of tetramer studies in the characterization of
HIV-specific CD8+ T-cells in HEPS populations is the decreased sensitivity of this
technique compared to ELISpot or bulk CTL assays.  The limit of detection for HLA-peptide
complexes is approximately 1/5000  [Altman (1996)], as compared to 1/50,000
for ELISpot [Lalvani (1997a)] and 1/100,000 for LDA [Goh (1999)]. Since the CD8+ T-cell precursor frequency in the
blood of HEPS populations is approximately 10-fold lower than in HIV-infected individuals
[Kaul (1999a)], in most cases these cells will be below the level of detection of the
HLA-peptide tetramer assay. There are no reports to date of tetramer-positive CD8+ cells in HEPS cohorts.
<P>

<b><font size="+1">HIV-specific CTL in HEPS populations</font></b><p>
It has become clear over the past decade that susceptibility to HIV
infection is not uniform, and that some individuals can be identified who do not develop
chronic HIV infection despite multiple exposures [Rowland-Jones (1995), Fowke (1996)]. The first reports of such cases in exposed seronegative homosexual men raised the possibility that transient infection might have occurred which could lead to protective immunity Imagawa89. Standard HIV-1 IgG ELISA
assays and Western blots are negative in these subjects, as are sensitive
HIV-1 PCR assays in the peripheral blood.  There nevertheless remains a possibility that
persistent infection has been established in such cases (Zhu et al.,
Sixth Conference on Retroviruses and Opportunistic Infections) but viraemia has been controlled
to levels below the limits of detection: therefore, these individuals are more accurately
referred to as HEPS than Exposed Uninfected (EU).
<P>
The association of HIV-specific CTL with non-progressive disease in HIV-infected persons [Pantaleo (1995), Harrer (1996c),
Betts (1999)], as well as the increased frequency of certain HLA class I alleles in HEPS populations [Plummer (1999)], has led several groups of
researchers to look for HLA class I restricted, HIV-specific CTL in these groups. HIV-specific CTL have
now been described in the peripheral blood of individuals exposed to HIV through a
number of routes, including heterosexual/homosexual sex
[RowlandJones (1995), Langlade-Demoyen (1994), Rowland-Jones (1998), Goh (1999), Bernard (1999)],
percutaneous exposure to infected blood [Pinto (1995), Bernard (1999)], and exposure to
maternal virus during pregnancy or delivery [Cheynier (1992), RowlandJones (1993), DeMaria (1994), Aldhous (1994)]. However, other investigators have not detected HIV-specific CTL in exposed uninfected infants Luzuriaga91: this discrepancy between reports may be because the exposure is largely at a single time-point or because the neonatal immune system is less able to mount a cellular immune response than adults. In animal models,
SIV-specific CTL have been associated with protection from SIV challenge in seronegative macaques exposed to either
HIV-2 [Putkonen (1995)] or low doses of SIV [Murphey-Corb (1999)]. Where attempts have been made to
quantitate CTL activity, the CTL in HEPS donors are usually present at a lower frequency than in
people with persistent HIV infection [Goh (1999), Kaul (1999a)]. CTL detection may also be
intermittent over time in a given individual [Goh (1999)]. This could be due to the levels of CTL
being close to the limits of detection of the currently available assays, or it may reflect a
genuine relationship between CTL numbers and the timing and extent of HIV exposure.  In
studies of HEPS donors with a single HIV exposure (through a needlestick injury or
at the time of birth) the detection of CTL has often been transient, with a
maximum duration of around 12 months following exposure [RowlandJones (1993), Pinto (1995)], although in one health
care worker with a series of needlestick injuries CTL activity was still
detectable 34 months after exposure [Bernard (1999)]. Resistance to HIV infection in
Caucasian HEPS populations has been associated with inherited defects in coreceptors
necessary for HIV cell entry [Liu (1996)], but these genetic defects do not account for
the lack of infection in the great majority of HEPS individuals [Fowke (1998), Goh (1999), Bernard (1999)].
<P>
The hypothesis that HIV-specific CTL may be a crucial element in decreased
susceptibility to HIV infection is suggested by the consistency with which
they have been described in various HEPS populations, by a number of different
investigators and using a variety of techniques. Despite the fact that the frequency of
some HIV-specific CTL in these individuals may be close to the limits of
detection, CTL can recognize a diverse array of HIV epitopes within a given HEPS individual
[RowlandJones (1995), Rowland-Jones (1998)]. The HIV epitopes recognized do not appear to fall within any one region of
the HIV genome, as responses have been described directed at <i>env</i>
[Cheynier (1992), Pinto (1995), Rowland-Jones (1998), Goh (1999), Fowke (1999)]; <i>gag</i>
[Cheynier (1992), RowlandJones (1993), RowlandJones (1995), Rowland-Jones (1998), Bernard (1999), Goh (1999)]; <i>nef</i>
Cheynier92,Langlade-Demoyen94,RowlandJones95,Rowland-Jones98,Bernard99,Goh99; and <i>pol</i>
[RowlandJones (1995), Rowland-Jones (1998), Bernard (1999), Goh (1999)]. Interestingly,
HIV-specific CTL have been recently been demonstrated in the genital tract
of the Nairobi HEPS prostitutes [Kau (1999a)], at the likely site of viral exposure.  It
might be hypothesized that a primed CTL response at the site of exposure would be more relevant in
protection against incident HIV infection than in blood, where HEPS CTL responses have
been previously described. This is consistent with the finding that mucosal
rather than blood CTL directed against an HIV envelope peptide were associated with
protection against gp160-vaccinia viral challenge in a mouse model Belyakov98c.
It has recently been reported that transient SIV infection of macaques following colonic
exposure led to the generation of mucosal SIV-specific CTL which were strongly associated with
protection against subsequent high dose SIV mucosal challenge [Murphey-Corb (1999)].
<P>

In most published studies, CTL are detected in the blood of approximately
30--60 of HEPS individuals examined. If the hypothesis that HIV-specific CTL play a
role in the protection of exposed seronegative subjects is correct, why are CTL not
detected in all HEPS donors? One key issue may be the sensitivity of the assay system. If,
as our experience suggests, the most sensitive method to detect CTL is the use of the
optimised specific epitope, either to stimulate CTL lines or in an ELISpot
assay, then studies will be limited by the availability of immunodominant epitopes for
the HLA haplotype of the donor. This is a particular problem for studies of
non-Caucasian donors exposed to non-clade B strains of HIV-1, where little epitope
mapping has been carried out [Dorrell (1999)]. Even for a well-studied HLA haplotype
such as A*0201 there is a hierarchy of CTL epitopes recognised by different donors
[Goulder (1997), Brander (1998)]. Moreover, this approach presupposes that the CTL responses of both resistant and infected
donors will be directed at the same epitopes, which is not necessarily logical. In
studies of CTL responses to peptides presented by the HLA molecule HLA-A*6802, which is
associated with resistance to HIV infection in the Nairobi cohort [MacDonald (1999)], we have
observed that the dominant response differs between infected and resistant donors
(R. Kaul, T. Dong, manuscript in preparation). This would not be surprising
if it is the case that some responses are more ``protective'' than others, but it does imply that the
use of epitopes defined in seropositive donors as tools to detect CTL in
HEPS donors may miss potentially important responses. Another factor is that CTL are
often only observed transiently, and this appears to be related to the duration and
extent of recent exposure. Certainly, the highest rate of CTLs detected to date has
been in a cohort of HEPS sex workers in Nairobi (R. Kaul, manuscript in preparation),
whose predicted antecedent exposure to HIV is extraordinarily high [Fowke (1996)].  Other factors, such
as intercurrent infection, may also influence the detection of CTL
responses (R. Kaul, manuscript in preparation). Finally, it is equally possible that the nature
of exposure has not been sufficient to elicit CTL responses and that HIV resistance is
mediated by other mechanisms. A number of other HIV-specific immune responses have also
been described in HEPS cohorts, including CD4+ T-cell responses associated with
lymphoproliferation [Goh (1999)], production of IL-2 [Clerici (1992), Clerici (1993), Clerici (1993a), Clerici (1994),
Beretta(1996a)] and -chemokines [Furci (1997), Wasik (1999)], CD8+ T-cell associated suppression of viral replication
[Levy (1998), Stranford (1999)], IgA in mucosa [Mazzoli (1997), Beyrer (1999), Kaul (1999)] and serum [Mazzoli (1999)], and antibodies to HLA
molecules [Beretta (1996a), Beretta (1996)] and CD4 [Burastero (1996)]. The
precise relationship between these different immune responses and
protection from subsequent infection remains unclear.
<P>
<b><font size="+1">Conclusions and future directions</font></b><br>
<P>
A number of important questions remain to be answered about the role of
HIV-specific CTL in HEPS donors. It is hard to explain what sort of
immunological priming would stimulate the cellular arm of the immune response so specifically
without leading to circulating antibodies: the mechanism of this priming
needs to be addressed. It is also important to understand why only a small minority of very
highly exposed people make these immune responses and resist HIV infection. It
seems likely that it is a particular conjunction of the nature of the viral
exposure (such as low-level mucosal exposure to a less efficiently replicating or
defective virus) and the ability of the immune system to respond unusually effectively to this
challenge. It has not so far been possible to link the immune responses of HEPS
donors with compelling evidence of transient HIV infection [Frenkel (1998)].
<P>
Although there is strong circumstantial evidence that HIV-specific CTL
responses in blood and mucosa are associated with resistance to HIV
infection in people with extensive HIV exposure who remain apparently uninfected, it remains
to be proven that these responses are actually mediating protection.
Epidemiological studies looking at the correlation of HIV resistance in high-risk cohorts
with the development of CTL responses during sustained HIV exposure should be helpful.
Some support for the CTL protection hypothesis comes from the macaque studies
described above. Further support has come from studies in which SCID mice
reconstituted with T-cells from HEPS (but not low-risk) donors were
resistant to HIV challenge: this protection was mediated by CD8+ cells [Zhang (1996)]. It
should be possible to use the SCID-hu mouse model to test whether CTL clones derived from resistant
donorsare associated with protection from challenge: in that case, it would be
valuable to compare the efficacy of clones from infected and HEPS donors in mediating
protection. It will be important to determine whether there is a qualitative difference
in the CTL from HEPS donors from those found in infected donors, such as an
increased T-cell receptor affinity which improves recognition of the infected
cell, or a pattern of cytokine and chemokine secretion which is better able
to suppress viral replication. It is also of great importance to know whether protection is
transient, in relation to the timing and extent of exposure, and would
therefore require regular boosting to be maintained. However, the ultimate test of
the role of HIV-specific CTL in protective immunity will come from studies of CTL-inducing
vaccines in human subjects. 
<P>
<b><font size="+1">Acknowledgments</font></b><br>
<P>
The unpublished work described in this review was supported by the Elizabeth
Glaser Paediatric AIDS Foundation and the Medical Research Councils of the
UK and Canada.
<P>
<b><font size="+1">References</font></b><br>
<P>
[Aldhous (1994)]<br>
M. C. Aldhous, K. C. Watret, J. Y. Mok, A. G. Bird,  K. S. Froebel.
Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.
<i>Clin Exp Immunol</i> <b>97</b>:61--7, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=94306754&Dopt=r">94306754</a>).
<P>
[Altman (1996)]<br>
J. D. Altman, P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael,  M. M. Davis.
Phenotypic analysis of antigen-specific T lymphocytes. <i>Science</i> <b>274</b>:94--6, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96412252&Dopt=r">96412252</a>).
<P>
[Belyakov (1998)]<br>
I. M. Belyakov, J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober,  J. A. Berzofsky.
The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and
enhancement of resistance by local administration of IL-12.
<i>J Clin Invest</i> <b>102</b>:2072--81, 1998.<br>
(Medline:  <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99072828&Dopt=r">99072828</a>).
<p>
[Beretta (1996a)]<br>
A. Beretta, L. Furci, S. Burastero, A. Cosma, M. E. Dinelli, L. Lopalco, C. DeSantis, G. Tambussi, E. Carrow, S. Sabbatani, M. Clerici, A. Lazzarin,  A. G. Siccardi.
HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection.
<i>Immunol Lett</i> <b>51</b>:39--43, 1996a.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96407290&Dopt=r">96407290</a>).
<p>
[Beretta (1996b)]<br>
A. Beretta, S. H. Weiss, G. Rappocciolo, R. Mayur, S. D. C., J. Quirinale, A. Cosma, P. Robbioni, G. M. Shearer,  J. A. Berzofsky et al.
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to
HLA class I antigens and T cells specific for HIV envelope.
<i>J Infect Dis</i> <b>173</b>:472--6, 1996b.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96162112&Dopt=r">96162112</a>).
<p>
[Bernard (1999)]<br>
N. F. Bernard, C. M. Yannakis, J. S. Lee,  C. M. Tsoukas.
Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons.
<i>J Infect Dis</i> <b>179</b>:538--47, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99137788&Dopt=r">99137788</a>).
<P>
[Betts (1999)]<br>
M. R. Betts, J. F. Krowka, T. B. Kepler, M. Davidian, C. Christopherson, S. Kwok, L. Louie, J. Eron, H. Sheppard,  J. A. Frelinger.
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type
1-infected long-term survivors [In Process Citation].
<i>AIDS Res Hum Retroviruses</i> <b>15</b>:1219--28, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99408512&Dopt=r">99408512</a>).
<p>
[Beyrer (1999)]<br>
C. Beyrer, A. W. Artenstein, S. Rugpao, H. Stephens, T. C. VanCott, M. L. Robb, M. Rinkaew, D. L. Birx, C. Khamboonruang, P. A.
Zimmerman, K. E. Nelson,  C. Natpratan.
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative
female sex workers in northern Thailand. Chiang Mai HEPS Working Group.
<i>J Infect Dis</i> <b>179</b>:59--67, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99059852&Dopt=r">99059852</a>).
<p>
[Brander (1998)]<br>
C. Brander, K. E. Hartman, A. K. Trocha, N. G. Jones, R. P. Johnson, B. Korber, P. Wentworth, S. P. Buchbinder, S. Wolinsky,
B. D. Walker,  S. A. Kalams.
Lack of strong immune selection pressure by the immunodominant, HLA-.
<i>J Clin Invest</i> <b>101</b>:2559--66, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98282291&Dopt=r">98282291</a>).
<P>
[Burastero (1996)]<br>
S. E. Burastero, D. Gaffi, L. Lopalco, G. Tambussi, B. Borgonovo, C. De Santis, C. Abecasis, P. Robbioni, A. Gasparri, A. Lazzarin,
  F. Celada, A. G. Siccardi,  A. Beretta.
Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals.
<i>AIDS Res Hum Retroviruses</i> <b>12</b>:273--80, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97063119&Dopt=r">97063119</a>).
<P>
[Carmichael (1993)]<br>
A. Carmichael, X. Jin, P. Sissons,  L. Borysiewicz. Quantitative analysis of the human immunodeficiency virus type 1
(HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr
virus in late disease.
<i>J Exp Med</i> <b>177</b>:249--56, 1993.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=93147714&Dopt=r">93147714</a>).
<P>
[Cheynier (1992)]<br>
R. Cheynier, P. Langlade-Demoyen, M. R. Marescot, S. B. S., G. Blondin, S. Wain-Hobson, C. Griscelli, E. Vilmer,  F. Plata.
Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers.
<i>Eur J Immunol</i> <b>22</b>:2211--2217, 1992.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=92387221&Dopt=r">92387221</a>).
<p>
[Clerici (1992)]<br>
M. Clerici, J. V. Giorgi, C. C. Chou, V. K. Gudeman, J. A. Zack, P. Gupta, H. N. Ho, P. G. Nishanian, J. A. Berzofsky,  G.
M. Shearer. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.
<i>J Infect Dis</i> <b>165</b>:1012--9, 92.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=92259993&Dopt=r">92259993</a>).
<p>
[Clerici (1994)]<br>
M. Clerici, J. M. Levin, H. A. Kessler, A. Harris, J. A. Berzofsky, A. L. Landay,  G. M. Shearer.
HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood.
<i>JAMA</i> <b>271</b>:42--6, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=94081557&Dopt=r">94081557</a>).
<p>
[Clerici  Shearer(1993)]<br>
M. Clerici  G. M. Shearer.
A TH1-->TH2 switch is a critical step in the etiology of HIV infection.
<i>Immunol Today</i> <b>14</b>:107--11, 1993.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=93221651&Dopt=r">93221651</a>).
<p>
[Clerici (1993)]<br>
M. Clerici, A. V. Sison, J. A. Berzofsky, T. A. Rakusan, C. D. Brandt, M. Ellaurie, M. Villa, C. Colie, D. J. Venzon, J. L.
Sever, et al. Cellular immune factors associated with mother-to-infant transmission of HIV.
<i>AIDS</i> <b>7</b>:1427--33, 1993.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=94107508&Dopt=r">94107508</a>).
<p>
[Czerkinsky (1988)]<br>
C. Czerkinsky, G. Andersson, H. P. Ekre, L. A. Nilsson, L. Klareskog, O. Ouchterlony.
Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.
<i>J Immunol Methods</i> <b>110</b>:29--36, 1988.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=88229169&Dopt=r">88229169</a>).
<p>
[De Maria (1994)]<br>
A. De Maria, C. Cirillo,  L. Moretta. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-
1-infected mothers. <i>J Infect Dis</i> <b>170</b>:1296--9, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95052856&Dopt=r">95052856</a>).
<p>
[Di Fabio (1994)]<br>
S. Di Fabio, I. N. Mbawuike, H. Kiyono, K. Fujihashi, R. B. Couch, J. R. McGhee.
Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma
producing CD8+ T cells.
<i>Int Immunol</i> <b>6</b>:11--9, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=94198224&Dopt=r">94198224</a>).
<p>
[Dorrell (1999)]<br>
L. Dorrell, T. Dong, G. S. Ogg, S. Lister, S. McAdam, T. Rostron, C. Conlon, A. J. McMichael,  S. L. Rowland-Jones.
Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in
Africa.
<i>J Virol</i> <b>73</b>:1708--14, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99099071&Dopt=r">99099071</a>).
<p>
[Dunbar (1999)]<br>
P. R. Dunbar, J. L. Chen, D. Chao, N. Rust, H. Teisserenc, G. S. Ogg, P. Romero, P. Weynants,  V. Cerundolo.
Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
<i>J Immunol</i> <b>162</b>:6959--62, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99288045&Dopt=r">99288045</a>).
<p>
[Dunbar (1998)]<br>
P. R. Dunbar, G. S. Ogg, J. Chen, N. Rust, P. van der Bruggen, V. Cerundolo. Direct isolation, phenotyping and cloning of low-frequency antigen-
specific cytotoxic T lymphocytes from peripheral blood. <i>Curr Biol</i> <b>8</b>:413--6, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98212077&Dopt=r">98212077</a>).
<p>
[Flanagan (1999)]<br>
K. L. Flanagan, M. Plebanski, P. Akinwunmi, E. A. Lee, W. H. Reece, K. J. Robson, A. V. Hill,  M. Pinder.
Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of
Plasmodium falciparum in West Africans. <i>Eur J Immunol</i> <b>29</b>:1943--54, 99.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99310130&Dopt=r">99310130</a>).
<p>
[Fowke (1998)]<br>
K. R. Fowke, T. Dong, S. L. Rowland-Jones, J. Oyugi, W. J. Rutherford, J. Kimani, P. Krausa, J. Bwayo, J. N. Simonsen, G. M.
Shearer,  F. A. Plummer. HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced
beta-chemokine production.
<i>AIDS Res Hum Retroviruses</i> <b>14</b>:1521--30, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99054020&Dopt=r">99054020</a>).
<p>
[Fowke (1999)]<br>
K. R. Fowke et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. 1999.
submitted.
<p>
[Fowke (1996)]<br>
K. R. Fowke, N. J. Nagelkerke, J. Kimani, J. N. Simonsen, A. O. Anzala, J. J. Bwayo, K. S. MacDonald, E. N. Ngugi,  F. A. Plummer.
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya.
<i>Lancet</i> <b>348</b>:1347--51, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97075955&Dopt=r">97075955</a>).
<p>
[Frenkel (1998)]<br>
L. M. Frenkel, J. I. Mullins, G. H. Learn, L. Manns-Arcuino, B. L. Herring, M. L. Kalish, R. W. Steketee, D. M. Thea, J. E. Nichols,
S. L. Liu, A. Harmache, X. He, D. Muthui, A. Madan, L. Hood, A. T. Haase, M. Zupancic, K. Staskus, S. Wolinsky, P. Krogstad,
J. Zhao, I. Chen, R. Koup, D. Ho, N. J. Roberts, et al. Genetic evaluation of suspected cases of transient HIV-1 infection of infants.
<i>Science</i> <b>280</b>:1073--7, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98248614&Dopt=r">98248614</a>).
<p>
[Furci (1997)]<br>
L. Furci, G. Scarlatti, S. Burastero, G. Tambussi, C. Colognesi, C. Quillent, R. Longhi, P. Loverro, B. Borgonovo, D. Gaffi,
E. Carrow, M. Malnati, P. Lusso, A. G. Siccardi, A. Lazzarin, A. Beretta.
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the
wild-type CCR- 5 allele.
<i>J Exp Med</i> <b>186</b>:455--60, 1997.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97383224&Dopt=r">97383224</a>).
<p>
[Gillespie (1999)]<br>
G. M. A. Gillespie et al. Functional heterogeneity and high frequencies of CMV-specific CD8+ T lymphocytes in healthy seropositive donors. 1999.
submitted.
<p>
[Goh (1999)]<br>
W. C. Goh, J. Markee, R. E. Akridge, M. Meldorf, L. Musey, T. Karchmer, M. Krone, A. Collier, L. Corey, M. Emerman,  M. J. McElrath.
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence
of inherited CCR5 coreceptor defects. <i>J Infect Dis</i> <b>179</b>:548--57, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99137789&Dopt=r">99137789</a>).
<p>
[Gotch (1990)]<br>
F. Gotch, D. Nixon, N. Alp, A. McMichael,  L. Borysiewicz. High frequency of memory and effector gag specific cytotoxic T
lymphocytes in HIV seropositive individuals. <i>Int Immunol</i> <b>2</b>:707, 1990.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=91190784&Dopt=r">91190784</a>).
<p>
[Goulder (1997)]<br>
P. Goulder, A. Sewell, D. Lalloo, D. Price, J. Whelan, J. Evans, G. Taylor, G. Luzzi, P. Giangrande, R. Phillips,  A. J. McMichael.
Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical
siblings with HLA-A*0201 are influenced by epitope mutation.
<i>J Exp Med</i> <b>8</b>:1423--33, 1997.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97272078&Dopt=r">97272078</a>).
<p>
[Hanke (1998)]<br>
T. Hanke, J. Schneider, S. G. Gilbert, A. V. S. Hill,  A. McMichael.
DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice.
<i>Vaccine</i> <b>16</b>:426--435, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98269949&Dopt=r">98269949</a>).
<p>
[Harrer (1996)]<br>
T. Harrer, E. Harrer, S. A. Kalams, T. Elbeik, S. I. Staprans, M. B. Feinberg, Y. Cao, D. D. Ho, T. Yilma, A. M. Caliendo,
R. P. Johnson, S. P. Buchbinder,  B. D. Walker.
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.
<i>AIDS Res Hum Retroviruses</i> <b>12</b>:585--92, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96291770&Dopt=r">96291770</a>).
<p>
[Herr (1998)]<br>
W. Herr, U. Protzer, A. W. Lohse, G. Gerken, K. H. Meyer zum Buschenfelde,  T. Wolfel.
Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and
seronegative persons at high risk for recent HIV exposure.
<i>J Infect Dis</i> <b>178</b>:260--5, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98314559&Dopt=r">98314559</a>).
<p>
[Imagawa (1989)]<br>
D. T. Imagawa, M. H. Lee, S. M. Wolinsky, K. Sano, F. Morales, S. Kwok, J. J. Sninsky, P. G. Nishanian, J. Giorgi, J. L. Fahey, et al.
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.
<i>N Engl J Med</i> <b>320</b>:1458--62, 89.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=89238486&Dopt=r">89238486</a>).
<p>
[Kaul (1999)]<br>
R. Kaul et al. HIV-1 specific mucosal cytotoxic T lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi. 1999.
submitted.
<p>
[Kaul (1999)]<br>
R. Kaul, D. Trabattoni, J. J. Bwayo, D. Arienti, A. Zagliani, F. M. Mwangi, C. Kariuki, E. N. Ngugi, K. S. MacDonald, T. B.
Ball, M. Clerici,  F. A. Plummer. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers.
<i>AIDS</i> <b>13</b>:23--9, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99223948&Dopt=r">99223948</a>).
<p>
[Koup (1991)]<br>
R. A. Koup, C. A. Pikora, K. Luzuriaga, D. B. Brettler, E. S. Day, G. P. Mazzara,  J. L. Sullivan.
Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro
quantitation of effector cell populations with p17 and p24 specificities.
<i>J Exp Med</i> <b>174</b>:1593--600, 1991.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=92078870&Dopt=r">92078870</a>).
<p>
[Lalvani (1997a)]<br>
A. Lalvani, R. Brookes, S. Hambleton, W. J. Britton, A. V. Hill, A. J. McMichael.
Rapid effector function in CD8+ memory T cells.
<i>J Exp Med</i> <b>186</b>:859--65, 1997a.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97439794&Dopt=r">97439794</a>).
<p>
[Lalvani (1997b)]<br>
A. Lalvani, T. Dong, G. Ogg, A. A. Patham, H. Newell, A. V. Hill, A. J. McMichael,  S. Rowland-Jones.
Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors.
<i>J Immunol Methods</i> <b>210</b>:65--77, 1997b.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98161691&Dopt=r">98161691</a>).
<p>
[Langlade-Demoyen (1994)]<br>
P. Langlade-Demoyen, N. Ngo-Giang-Huong, F. Ferchal, E. Oksenhendler.
Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients.
<i>J Clin Invest</I> <b>93</b>:1293--7, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=94179479&Dopt=r">94179479</a>).
<p>
[Larsson (1999)]<br>
M. Larsson, X. Jin, B. Ramratnam, G. S. Ogg, J. Engelmayer, M. A. Demoitie, A. J. McMichael, W. I. Cox, R. M. Steinman, D.
Nixon, N. Bhardwaj. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.
<i>AIDS</i> <b>13</b>:767--77, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99284267&Dopt=r">99284267</a>).
<p>
[Levy (1998)]<br>
J. A. Levy, F. Hsueh, D. J. Blackbourn, D. Wara,  P. S. Weintrub. CD8 cell noncytotoxic antiviral activity in human immunodeficiency
virus-infected and -uninfected children.
<i>J Infect Dis</i> <b>177</b>:470--2, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98126016&Dopt=r">98126016</a>).
<p>
[Liu (1996)]<br>
R. Liu, W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup,  N. R. Landau.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
<i>Cell</i> <b>86</b>:367--77, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96339434&Dopt=r">96339434</a>).
<p>
[Lubaki (1994)]<br>
M. N. Lubaki, M. A. Egan, R. F. Siliciano, K. J. Weinhold,  R. C. Bollinger.
A novel method for detection and ex vivo expansion of HIV type 1- specific cytolytic T lymphocytes.
<i>AIDS Res Hum Retroviruses</i> <b>10</b>:1427--31, 1994.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95194702&Dopt=r">95194702</a>).
<p>
[Luzuriaga (1991)]<br>
K. Luzuriaga, R. A. Koup, C. A. Pikora, D. B. Brettler,  J. L. Sullivan.
Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.
<i>J Pediatr</i> <b>119</b>:230--6, 91.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=91318378&Dopt=r">91318378</a>).
<p>
[MacDonald (1999)]<br>
G. M. A. MacDonald et al. The influence of HLA antigens on susceptibility and resistance to HIV-1 in sexually exposed prostitutes. 1999.
submitted.
<p>
[Mazzoli (1999)]<br>
S. Mazzoli, L. Lopalco, A. Salvi, D. Trabattoni, S. Lo Caputo, F. Semplici, M. Biasin, C. Bl, A. Cosma, C. Pastori, F. Meacci,
F. Mazzotta, M. L. Villa, A. G. Siccardi,  M. Clerici. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing
activity in the serum of exposed seronegative partners of HIV- seropositive persons.
<i>J Infect Dis</i> <b>180</b>:871--5, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99367601&Dopt=r">99367601</a>).
<p>
[Mazzoli (1997)]<br>
S. Mazzoli, D. Trabattoni, S. Lo Caputo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, M. L.
Fusi, N. Tofani, M. Biasin, M. L. Villa, F. Mazzotta,  M. Clerici.
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
<i>Nat Med</i> <b>3</b>:1250--7, 1997.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98022658&Dopt=r">98022658</a>).
<p>
[Miyahira (1995)]<br>
Y. Miyahira, K. Murata, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. M. Rodrigues,  F. Zavala.
Quantification of antigen specific CD8+ T cells using an ELISPOT assay.
<i>J Immunol Methods</i> <b>181</b>:45--54, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95248136&Dopt=r">95248136</a>).
<p>
[Moss (1995)]<br>
P. A. H. Moss, S. L. Rowland-Jones, P. M. Frodsham, S. McAdam, P. Giangrande, A. McMichael,  J. I. Bell.
Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.
<i>Proc Nat Acad Sci USA</i> <b>92</b>:5773--5777, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95320157&Dopt=r">95320157</a>).
<p>
[Murphey-Corb (1999)]<br>
M. Murphey-Corb, L. A. Wilson, A. M. Trichel, D. E. Roberts, K. Xu, S. Ohkawa, B. Woodson, R. Bohm,  J. Blanchard.
Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the
colonic mucosa. <i>J Immunol</I> <b>162</b>:540--9, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99101522&Dopt=r">99101522</a>).
<p>
[Nixon (1988)]<br>
D. Nixon, A. Townsend, J. Elvin, C. Rizza, J. Gallway,  A. McMichael.
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides (p24 KRWIILGLNKIVRMY).
<i>Nature</i> <b>336</b>:484--487, 1988.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=89057146&Dopt=r">89057146</a>).
<p>
[Ogg (1998)]<br>
G. S. Ogg, X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo,
A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon,  A. J. McMichael. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma
load of viral RNA. <i>Science</i> <b>279</b>:2103--6, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98182444&Dopt=r">98182444</a>).
<p>
[Ogg  McMichael(1999)]<br>
G. S. Ogg  A. J. McMichael. Quantitation of antigen-specific CD8+ T-cell responses.
<i>Immunol Lett</i> <b>66</b>:77--80, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99217687&Dopt=r">99217687</a>).
<p>
[Pantaleo (1995)]<br>
G. Pantaleo, S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, L.
K. Schrager, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.
<i>N Engl J Med</i> <b>332</B>:209--16, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95107359&Dopt=r">95107359</a>).
<p>
[Pinto (1995)]<br>
L. A. Pinto, J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Landay,  G. M. Shearer.
Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.
<i>J. Clin. Invest.</i> <b>96</b>:867--876, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95362849&Dopt=r">95362849</a>).
<p>
[Plata (1987)]<br>
F. Plata, B. Autran, L. P. Martins, S. Wain-Hobson, M. Raphael, C. Mayaud, M. Denis, J. M. Guillon,  P. Debre.
AIDS virus-specific cytotoxic T lymphocytes in lung disorders.
<i>Nature</i> <b>328</b>:348--51, 1987.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=87258274&Dopt=r">87258274</a>).
<p>
[Plummer (1999)]<br>
F. A. Plummer, T. B. Ball, J. Kimani,  K. R. Fowke. Resistance to HIV-1 infection among highly exposed sex workers in
Nairobi: what mediates protection and why does it develop?
<i>Immunol Lett</i> <b>66</b>:27--34, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99217681&Dopt=r">99217681</a>).
<p>
[Putkonen (1995)]<br>
P. Putkonen, L. Walther, Y. J. Zhang, S. L. Li, C. Nilsson, J. Albert, P. Biberfeld, R. Thorstensson,  G. Biberfeld.
Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine.
<i>Nat Med</i> <b>1</b>:914--8, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96071597&Dopt=r">96071597</a>).
<p>
[Quiding (1991)]<br>
M. Quiding, I. Nordstrom, A. Kilander, G. Andersson, L. A. Hanson, J. Holmgren,  C. Czerkinsky.
Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production
and evokes local immunological memory. <i>J Clin Invest</i> <b>88</b>:143--8, 1991.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=91277273&Dopt=r">91277273</a>).
<P>
[Rowland-Jones (1998)]<br>
S. L. Rowland-Jones, T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi,
J. Bwayo, K. S. MacDonald, A. J. McMichael,  F. A. Plummer. Cytotoxic T cell responses to multiple conserved HIV epitopes in
HIV- resistant prostitutes in Nairobi. <i>J Clin Invest</i> <b>102</b>:1758--65, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99021675&Dopt=r">99021675</a>).
<p>
[Rowland-Jones  McMichael(1995)]<br>
S. L. Rowland-Jones  A. McMichael. Immune responses in HIV-exposed seronegatives: have they repelled the virus?
<i>Curr Opin Immunol</i> <b>7</b>:448--55, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96085780&Dopt=r">96085780</a>).
<p>
[Rowland-Jones (1993)]<br>
S. L. Rowland-Jones, D. F. Nixon, M. C. Aldhous, F. Gotch, K. Ariyoshi, N. Hallam, J. S. Kroll, K. Froebel,  A. McMichael.
HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.
<i>Lancet</i> <b>341</b>:860--861, 1993.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=93218363&Dopt=r">93218363</a>).
<p>
[Rowland-Jones (1995)]<br>
S. L. Rowland-Jones, J. Sutton, K. Ariyoshi, T. Dong and , F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah,
M. Takiguchi, T. Schultz, A. McMichael,  H. Whittle. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.
<i>Nature Medicine</i> <b>1</b>:59--64, 1995.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=96071373&Dopt=r">96071373</a>).
<p>
[Schmittel (1997)]<br>
A. Schmittel, U. Keilholz,  C. Scheibenbogen. Evaluation of the interferon-gamma ELISPOT-assay for quantification
of peptide specific T lymphocytes from peripheral blood.
<i>J Immunol Methods</i> <b>210</b>:167--74, 1997.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98179122&Dopt=r">98179122</a>).
<p>
[Stranford (1999)]<br>
S. A. Stranford, J. Skurnick, D. Louria, D. Osmond, S. Y. Chang, J. Sninsky, G. Ferrari, K. Weinhold, C. Lindquist,  J. A. Levy.
Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response.
<i>Proc Natl Acad Sci USA</i> <b>96</b>:1030--5, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99128357&Dopt=r">99128357</a>).
<p>
[Tan (1999a)]<br>
L. C. Tan, N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O'Callaghan, S. Rowland-Jones, A. J. McMichael, A. B. Rickinson,  M. F. Callan.
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
<i>J Immunol</i> <b>162</b>:1827--35, 1999a.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99138871&Dopt=r">99138871</a>).
<p>
[Tan (1999b)]<br>
R. Tan, X. Xu, G. S. Ogg, P. Hansasuta, T. Dong, T. Rostron, G. Luzzi, C. P. Conlon, G. R. Screaton, A. J. McMichael, S. Rowland-Jones.
Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome.
<i>Blood</i> <b>93</b>:1506--10, 1999b.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99155328&Dopt=r">99155328</a>).
<p>
[van Baalen (1993)]<br>
C. A. van Baalen, M. R. Klein, A. M. Geretti, R. I. P. M. Keet, F. Miedema, C. A. C. M. van Els,  A. D. M. E. Osterhaus.
Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T-cells: cytotoxic T-lymphocyte epitopes and
precursor frequencies.
<i>AIDS</i> <b>7</b>:781--786, 1993.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=93371704&Dopt=r">93371704</a>)
<p>
[Walker (1987)]<br>
B. D. Walker, S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch,  R.
T. Schooley. HIV-specific cytotoxic T lymphocytes in seropositive individuals.
<i>Nature</i> <b>328</b>:345--8, 1987.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=87258273&Dopt=r">87258273</a>).
<p>
[Wasik (1999)]<br>
T. J. Wasik, J. Bratosiewicz, A. Wierzbicki, V. E. Whiteman, R. R. Rutstein, S. E. Starr, S. D. Douglas, D. Kaufman, A. V. Sison,
M. Polansky, H. W. Lischner,  D. Kozbor. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission.
<i>J Immunol</i> <b>162</b>:4355--64, 1999.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=99218467&Dopt=r">99218467</a>).
<p>
[Wilson (1998)]<br>
J. D. Wilson, G. S. Ogg, R. L. Allen, P. J. Goulder, A. Kelleher, A. K. Sewell, C. A. O'Callaghan, S. L. Rowland-Jones, M.
F. Callan, A. J. McMichael. Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific.
<i>J Exp Med</i> <b>188(4)</b>:785--90, 1998.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=98372770&Dopt=r">98372770</a>).
<p>
[Zhang (1996)]<br>
C. Zhang, Y. Cui, S. Houston,  L. J. Chang. Protective immunity to HIV-1 in SCID/beige mice reconstituted with
peripheral blood lymphocytes of exposed but uninfected individuals.
<i>Proc Natl Acad Sci USA</i> <b>93</b>:14720--5, 1996.<br>
(Medline: <a href="http://www3.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97121455&Dopt=r">97121455</a>).


</td></tr>
	    <tr><td><table bgcolor="white" width="100%" align="center" cellpadding="0" cellspacing="0" border="0">
  <tr><td>&nbsp;</td></tr>
  <tr><td colspan=2 align=center>Questions or comments? Contact us at <a href="mailto:seq-info@t10.lanl.gov"><font color="#8f8fbd" face="helvetica">seq-info@t10.lanl.gov</font></a></td></tr>
  <tr><td>&nbsp;</td></tr>
</table>



</td></tr>
	  </table>  
        </td>
      </tr>	
    </table>
  </body>
</html>      

<!-- no autohandlers upstream -->


